- Company
- The sales of Dupixent tripled in a year
- by Kim, Jin-Gu Dec 2, 2020 06:06am
- Sales of Dupixent (Dupilumab), a treatment for severe atopic dermatitis, are increasing. Sales have increased since it was applied to health insurance benefits in January of this year. It posted a cumulative sales of &8361;15.6 billion in the third quarter, and is expected to exceed &8361;20 billion by the end of the year. According to I
- Policy
- 3 reimbursed Spinraza use applications from Oct. all cleared
- by Lee, Hye-Kyung Dec 2, 2020 06:05am
- The South Korean health authority has approved of all three cases submitted preliminary approval applications from last month seeking to use spinal muscular atropy (SMA) treatment Spinraza with coverage. Four months after a reimbursement approval, the drug user has to submit an administration monitoring reports for approval on maintenance dos
- Policy
- 3 month-lasting birth control injection withdraws from Korea
- by Lee, Tak-Sun Dec 1, 2020 06:19am
- Pfizer’s contraceptive injection Sayana (medroxyprogesterone acetate) initially received the public’s limelight for the convenience of injecting once every three months, but it has decided to withdraw from the South Korean market. The injection even extended the post-marketing surveillance (PMS) period and showed its commitment to st
- Company
- Talzenna didn’t pass the Cancer Assessment Committee
- by Eo, Yun-Ho Dec 1, 2020 06:15am
- The government is conservative about breast cancer-related insurance benefits for PARP inhibitors. According to related industries, Pfizer's Talzenna (Talazoparib) was submitted to the HIRA's Cancer Assessment Committee held on the 25th, but failed. As the range of indications for breast cancer of PARP (poly ADP ribose polymerase) inhibito
- Company
- Lynparza, a big change in the tx of BRCA-mutated cancer
- by Dec 1, 2020 06:15am
- "Most ovarian cancers are found in the 3rd to 4th stage because there is no subjective symptoms. After the first treatment, 70% recur within 3 years, and the 5-year survival rate is only 38%. Maintained by the release of Lynparza. The prognosis of patients is greatly improved through therapy. In particular, the first published 5-year follow-up r
- Policy
- NSCLC treatment Vizimpro 30 mg KRW 25,684 per tablet
- by Kim, Jung-Ju Dec 1, 2020 06:15am
- From December, Pfizer Pharmaceutical Korea’s non-small cell lung cancer (NSCLC) treatment Vizimpro (dacomitinib) 30 mg tablet would be priced at 25,684 won with the healthcare reimbursement. The insured pricing for Amgen Korea’s osteoporosis treatment Evenity (romososumab) injection prefilled syringe was set at 123,700 won. South Korea’s
- Company
- Whanin ends sales of Sandoz antidepressants
- by Dec 1, 2020 06:15am
- Sandoz's supply of four antidepressants, which Whanin supplied, will end this year. According to the drug distribution industry on the 27th, Whanin announced that the supply of four Sandoz antidepressants will be suspended as the contract with Sandoz ends on the 30th. The items are ▲Sandoz Escitalopram 5·10·15mg ▲Paroxetine 20mg ▲S
- Company
- TNBC treatment adds newly approved immunotherapy option
- by Eo, Yun-Ho Nov 30, 2020 06:21am
- Anticipation is heightening for the use of an immunotherapy Tecentriq (atezolizumab) in the triple-negative breast cancer (TNBC) treatment scene. Pharmaceutical industry sources reported Roche Korea’s PD-L1 inhibiting immunotherapy Tecentriq has recently successfully expanded the indication as a first-line treatment for TNBC, combined wi
- Policy
- Reimbursement procedure for RSA drugs has been disclosed
- by Lee, Hye-Kyung Nov 30, 2020 06:21am
- The amount of risk-sharing refunds paid to patients by The NHIS for the last five years under the Risk Sharing Agreement (RSA) contract reached &8361;5.46 billion. More than half of them, or &8361;3 billion, were paid out from January to September of this year. Nam-seon Choi, head of the NHIS drug price negotiation department, recently r
- Company
- Can HPV vaccine for men be included in the NIP?
- by Eo, Yun-Ho Nov 30, 2020 06:21am
- It is worth paying attention to whether vaccinating men with HPV vaccine can be included in the National Immunization Program (NIP). Earlier this month, Hye-young Choi, a member of Democratic Party of Korea said that the human papillomavirus (HPV) vaccine NIP, which is currently being conducted only for 12-year-old girls, includes both men
